The article presents a snapshot of a highly active, albeit somewhat fragmented, landscape within Maryland’s biopharma sector – a characteristic pattern of “distributed innovation” where multiple companies are tackling similar, complex challenges. The sequencing reveals a classic ‘motte-and-bailey’ tactic, presenting the regulatory delays for Regenxbio’s gene therapy as a simple question of “approval” versus “delay,” obscuring the deeply complex process of FDA review and the potential for unfores...